Literature DB >> 24943299

Genetics of primary aldosteronism.

John W Funder1.   

Abstract

Primary aldosteronism (PA) accounts for ∼10% of hypertension, which is commonly caused by an aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia. Germline mutations producing PA are considered rare and termed familial hyperaldosteronism (FH) [1, 2, 3]. Since early 2011, a series of somatic mutations confined to the adrenal cortex has been reported, accounting for about half of APA. These mutations are in genes encoding components of the Kir 3.4 (GIRK4) potassium channel (KCNJ5), sodium/potassium and calcium ATPases (ATP1A1 and ATP2B3) and a voltage-dependent C-type calcium channel (CACNA1D). FH-1 (glucocorticoid-remediable hyperaldosteronism) results from a chimeric gene (5'-end of CYP11B1 fused to 3'-end of CYP11B2) and accounts for ∼1% of PA. FH-3 is very rare, is caused by bilateral expression of mutant KCNJ5 and usually results in florid hyperaldosteronism requiring early bilateral adrenalectomy. FH-2 is the most common form of hereditary PA (2 first-degree relatives with either an APA or bilateral adrenal hyperplasia) and currently thought to represent ∼6% of PA; the true prevalence may be considerably higher. The mutation(s) causing FH-2 are unknown but appear dominant, as is the case for FH-1 and FH-3. No studies have been done on possible recessive forms of PA.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943299     DOI: 10.1159/000360870

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  6 in total

1.  Monozygotic twins discordant for primary aldosteronism: a case report.

Authors:  Y Kobayashi; K Yatsu; K Nakata-Shimokihara; N Inoue; T Fujikawa; N Hirawa; S Umemura; F Satoh; G P Rossi; K Tamura
Journal:  J Hum Hypertens       Date:  2017-05-25       Impact factor: 3.012

2.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

Review 3.  5th International ACC Symposium: The New Genetics of Benign Adrenocortical Neoplasia: Hyperplasias, Adenomas, and Their Implications for Progression into Cancer.

Authors:  Lawrence S Kirschner; Constantine A Stratakis
Journal:  Horm Cancer       Date:  2015-12-18       Impact factor: 3.869

4.  Glucocorticoid-remediable aldosteronism in a young adult with a family history of Conn's syndrome.

Authors:  Heiko Methe; Sinan Pehlivanli
Journal:  Clin Case Rep       Date:  2018-01-15

Review 5.  Disorders of the adrenal cortex: Genetic and molecular aspects.

Authors:  Georgia Pitsava; Andrea G Maria; Fabio R Faucz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 6.  A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy.

Authors:  Viola Sanga; Teresa Maria Seccia; Gian Paolo Rossi
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.